BML-286

SKU: orb2665223

Description

BML-286 is a small molecule WNT pathway activator that enhances β-catenin/TCF-dependent transcription. It is utilized in cancer research, including studies on leukemia, melanoma, and carcinomas, and has applications in investigating degenerative diseases in both cellular and animal models.

Research Area

Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 294891-81-9
• MW: 374.39
• Purity: 98.44%
• Formula: C₂₂H₁₈N₂O₄
• SMILES: O=C(O)C=1C=CC=CC1NC(=O)C=2C=CC=C(C2)NC(=O)CC=3C=CC=CC3
• Target: Wnt/beta-catenin

Bioactivity

• Target IC50:
  PDZ structural domain of Dishevelled protein:10.6 μM (Kd)|Wnt pathway-dependent PC3 cells:12.5 μM
• In Vitro:
  BML-286 (Compound 3289-8625) inhibits the Wnt signaling pathway by binding to the PDZ structural domain of Dishevelled (Dvl) protein (Kd = 10.6 μM). In addition, BML-286 blocked Wnt3a-induced transcriptional activity and effectively inhibited the growth of Wnt pathway-dependent prostate cancer PC-3 cells in vitro (IC50 = 12.5 μM).

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BML286

Compound Identifiers

PubChem CID

5221450